Activist Investor Demands Exelixis Cut R&D Spending And Learn From Peers
CEO Pushes Back On R&D Spending Cut Calls
Executive Summary
The mid-sized company is under siege from hedge fund Farallon and faces a fight over its R&D strategy to follow aging blockbuster Cabometyx.
You may also be interested in...
Exelixis’ Cabometyx R&D On Track Despite Pivotal Kidney Cancer Setback
The US firm’s Cabometyx has missed the mark in combination with Roche’s Tecentriq in a challenging kidney cancer setting, but analysts argue the setback is minimal as they highlight two major readouts coming this year.
Novo Nordisk Broke UK Rules By ‘Disparaging’ Rival Eli Lilly
The Danish company has once again broken UK industry rules, this time by looking to get the upper hand on its GLP-1 receptor agonist market rival Eli Lilly.
Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.